OSE Immunotherapeutics presented promising data from preclinical experiments of its investigational treatment OSE-127 (Effi-7) for inflammatory bowel disease (IBD) at FOCIS 2017, the Federation of Clinical Immunology Societies, held June 14-17 in Chicago. The drug, an antibody that blocks the alpha chain of the interleukin-7 receptor (IL-7R), prevented T-cells (immune cells) from entering gut tissue both in cells and tissue samples from IBD patients, thereby reducing inflammation. "Strengthened by first-class academic collaborations, our studies demonstrate a differentiated mechanism of action for OSE-127 able to fight pathologic [disease-causing] local homing of inflammatory T lymphocytes,” Nicolas Poirier, the French company's chief scientific officer, said in a press release. Researchers believe that IL-7R, also called CD127, controls migration of so-called effector T-cells in the tissue, particularly in the gut. Earlier studies have shown that blocking IL-7R prevents effector T-cells from traveling to the tissue while having no impact on regulatory T-cells. This is an important line of defense — a favorable situation in people with an autoimmune condition such as IBD. Presented in the study, "IL-7 pathway controls human T cell homing to the gut and culminates in inflammatory bowel disease mucosa," the experiments showed that by stopping T-cell migration, OSE-127 prevented the destruction of gut mucosa.